Abstract: PARIPEX - INDIAN JOURNAL OF RESEARCH | Volume - 9 | Issue - 8 | August - 2020 | PRINT ISSN No. 2250 - 1991 | DOI : 10.36106/paripex ORIGINAL RESEARCH PAPER Medicine IVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: KEY WORDS: RESULTS OF AN OPEN-LABEL RANDOMIZED CLINICAL STUDY Dr. Naveen Kishoria* Dr. S.L Mathur Dr.Veeram Parmar Dr. Rimple Jeet Kaur Dr. Harish Agarwal Dr. B.S Parihar Department of Medicine, Dr. S. N. Medical College, Jodhpur*Corresponding Author Dr Somil Verma Department of Medicine, Dr. S. N. Medical College, Jodhpur Department of Medicine, Dr. S. N. Medical College, Jodhpur Department of Medicine, Dr. S. N. Medical College, Jodhpur Department of Pharmacology, Dr. S. N. Medical College, Jodhpur Department of Medicine, Dr. S. N. Medical College, Jodhpur Department of Medicine, Dr. S. N. Medical College, Jodhpur BACKGROUND: A cluster of pneumonia cases of unknown etiology was reported from the city of Wuhan, in the Hubei province of China, in December 2019. A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the causative agent of the disease which was subsequently termed as the coronavirus disease (COVID-19) by the World Health Organization (WHO). SARS-CoV-2 mainly affects the lower respiratory tract and manifests as pneumonia in humans.1 The incidence of COVID-19 continues to rise, with 9,653,048 laboratory-confirmed cases and 491,128 deaths worldwide and India has reported 508,953 cases and 15,685 deaths till 27th, June 2020.2 The clinical manifestations of COVID-19 range from fever, cough, fatigue, sore throat, shortness of breath and less common symptoms such as headache, nausea and diarrhea.3,4 The most common abnormalities in vital signs are increased temperature and tachypnea. The most common radiological findings are bilateral pulmonary infiltrates, ground glass opacities and consolidation. The most common findings associated with severe disease are older age, d- dimer levels greater, higher SOFA score, elevated IL-6, increased Lactate Dehydrogenase, hyperferritinemia and lymphopenia on admission.5,6The most common complications are sepsis, respiratory failure, acute respiratory distress syndrome (ARDS), cardiac injury and acute kidney injury. As per WHO the mild COVID-19 illness may include: uncomplicated upper respiratory tract viral infection symptoms such as fever, fatigue, cough (with or without sputum production), anorexia, malaise, muscle pain, sore throat, dyspnea, nasal congestion, or headache. Rarely, patients may also present with diarrhoea, nausea, and vomiting.7 According to a recent Chinese study, about 80% of patients present with mild disease and the overall case-fatality rate is about 2.3% but reaches 8.0% in patients aged 70 to 79 years and 14.8% in those aged ≥80 years.7 However, there is probably an important number of asymptomatic carriers in the population, and thus the mortality rate is probably overestimated. India is facing the COVID-19 wave with more than 145,380 cases, as of May 2020. Thus, there is an urgent 50 need for an effective treatment to treat asymptomatic patients and to decrease the duration of virus carriage in order to limit the transmission in the community. Among candidate drugs to treat COVID-19, repositioning of old drugs for use as antiviral treatment is an interesting strategy because knowledge on safety profile, side effects, posology and drug..